PARP14 is a writer, reader, and eraser of mono-ADP-ribosylation

Research output: Contribution to journalArticlepeer-review

Abstract

PARP14/BAL2 is a large multidomain enzyme involved in signaling pathways with relevance to cancer, inflammation, and infection. Inhibition of its mono-ADP-ribosylating PARP homology domain and its three ADP-ribosyl binding macro domains has been regarded as a potential means of therapeutic intervention. Macrodomains-2 and -3 are known to stably bind to ADP-ribosylated target proteins, but the function of macrodomain-1 has remained somewhat elusive. Here, we used biochemical assays of ADP-ribosylation levels to characterize PARP14 macrodomain-1 and the homologous macrodomain-1 of PARP9. Our results show that both macrodomains display an ADP-ribosyl glycohydrolase activity that is not directed toward specific protein side chains. PARP14 macrodomain-1 is unable to degrade poly(ADP-ribose), the enzymatic product of PARP1. The F926A mutation of PARP14 and the F244A mutation of PARP9 strongly reduced ADP-ribosyl glycohydrolase activity of the respective macrodomains, suggesting mechanistic homology to the Mac1 domain of the SARS-CoV-2 Nsp3 protein. This study adds two new enzymes to the previously known six human ADP-ribosyl glycohydrolases. Our results have key implications for how PARP14 and PARP9 will be studied and how their functions will be understood.

Original languageEnglish
Article number105096
JournalThe Journal of biological chemistry
Volume299
Issue number9
DOIs
Publication statusPublished - 2023 Jul 26

Subject classification (UKÄ)

  • Biochemistry and Molecular Biology
  • Chemical Sciences

Fingerprint

Dive into the research topics of 'PARP14 is a writer, reader, and eraser of mono-ADP-ribosylation'. Together they form a unique fingerprint.

Cite this